Given the cumulating data on LRG-1 and cancer progression, further supported by mouse data indicating improved tumor control upon LRG-1 inhibition in combination with ICB, we envision that LRG1 could become, not only a biomarker, but also a possible target for combination therapy with ICB for patients with an unfavorable response after treatment with neoadjuvant immunotherapy. This evidence concerns the gene LRG1 and cancer.